Cone photoreceptors mediate daylight vision and are the primary cells responsible for vision in humans. Cone dysfunction leads to poor quality daylight vision because rod photoreceptors become saturated and non-functional at high light levels. Here we demonstrate that in mice lacking cone function, AAV-mediated over-expression of Rgs9anchor protein (R9AP), a critical component of the GTPase complex that mediates the deactivation of the phototransduction cascade, results in desensitization of rod function and a "photopic shift" of the rod-driven electroretinogram. This treatment enables rods to respond to brighter light (up to ~2.0 log) with increased visually-evoked cortical responses to high intensity stimulation. These results suggest that AAV-mediated transfer of R9ap into rods might be used to improve daylight vision in humans visually handicapped by cone dysfunction.
Introduction
In most mammals, including mice and humans, rod photoreceptors, which mediate vision in dim light, far outnumber cone photoreceptors 1 . However, for humans in an industrialized world where artificial illumination facilitates cone function throughout the day, rod-mediated vision is less critical. Many individuals with congenitally absent rod function are identified only incidentally and, in fact, may not recognize their abnormal vision 2, 3 . In contrast, individuals affected by cone dysfunction are typically symptomatic and often suffer visual impairment dependent on the degree of their cone dysfunction. In some conditions, when the cones are lost or dysfunctional, rods remain well preserved. Although rods are able to detect very low levels of light, they become saturated at high light levels. Cones, on the other hand, are less sensitive, but are capable of processing large amounts of light and are continuously functional in bright daylight. This difference is, in part, due to the efficiency of the deactivation machinery of phototransduction, the GTPase complex composed of RGS9, R9AP (also known as RGS9BP), and Gß5 4, 5 . RGS9 is the catalytic component that hydrolyses the GTP coupled to the G-protein, whereas R9AP and Gß5 are the essential constitutive subunits 4, 5 .
Importantly, R9AP tethers the complex to the disc membrane in the photoreceptor outer segment where phototransduction signaling takes place 6 . Expression of R9AP determines the level of the GTPase complex, such that any RGS9 produced in excess of R9AP is quickly degraded 7 . Over-expression of R9AP in murine rods is sufficient to increase the GTPase activity and to substantially increase the speed of their deactivation kinetics as evidenced by single cell recordings 8 and flicker electroretinogram (ERG) responses in transgenic mice 9 .
In cones, RGS9 expression has been estimated to be ~10-fold higher than in rods 10, 11 . This provides a basis for the ability of the cones to recover quickly from light exposure and thus maintain function in response to a continuous light stimulus. It also allows cones to respond to more rapid stimulation. Indeed, patients with bradyopsia, who have delayed deactivation of the phototransduction cascade caused by genetic defects in RGS9 or R9AP, have a profound impairment of cone-mediated vision including day blindness and reduced ability to see moving objects 12, 13 . Rod-mediated vision is less affected by the same mutation. Cone dysfunction/degeneration with relatively preserved rods are observed in a few forms of retinal dystrophies, such as cone dystrophy, complete and incomplete achromatopsia, and conerod dystrophy 14, 15, 16, 17, 18 , as well as more frequent disease such as early-onset high myopia 19, 20 . In these conditions, patients are often obliged to rely heavily on rod mediated vision even under light resulting in from debilitating photophobia of unknown cause and day blindness caused by low bleaching threshold of the rods.
In this study, we sought to define the therapeutic potential of AAV-mediated transfer of the murine R9ap gene into rods using murine models lacking cone vision. Electrophysiological and behavioral tests showed that vector-mediated R9AP over-expression in adult mice can increase the refresh rate of rods, allowing them to respond to higher light levels thereby 6 improving daylight vision.
Results

R9AP over-expression in rods and increased speed of photoreceptor deactivation
To study the effect of AAV-mediated R9AP over-expression on the GTPase complex in the rods, the level and distribution of the catalytic component, RGS9, was examined following subretinal injection of rAAV2/8.Rho.mR9ap in Cnga3-/-mice. These mice have normal rod function but absent cone function and serve as an animal model of achromatopsia, a rare but most severe form of cone dystrophy with a complete absence of cone function from birth.
Four weeks later, the retina showed increased immunoreactivity against RGS9 in treated compared to untreated eyes ( Fig. 1A ). This was recognized most obviously as a difference in the distribution of the RGS9. In the treated eyes, RGS9 expression was recognized throughout the entire photoreceptor layer, including the outer nuclear layer and outer plexiform layer, whereas the expression was confined to the inner and the outer segments in the untreated contralateral eye. Western blot analysis confirmed the increased RGS9 protein expression in the treated retina ( Fig. 1B) . These results confirm the prediction that an overexpression of R9AP increases the level of RGS9 and the GTPase complex.
Next we studied the functional effect of R9AP over-expression on rod phototransduction using paired-flash ERGs 21 . In this paradigm, a pair of flashes of equal intensity are delivered with a variable inter-stimulus interval and the recovery of the second response relative to the first is measured. In the rod photoreceptors, the speed of the a-wave (originating from photoreceptors) recovery is dependent on the deactivation speed of their phototransduction signaling 21 
Photopic shift of rod function by over-expression of R9AP
To define the effects of an increased GTPase activity and deactivation speed of phototransduction achieved through the overexpression of R9AP on the rod photoreceptor function, dark-adapted 6 Hz flicker ERGs were recorded using flashes of incremental intensities. In this paradigm, untreated rods respond to flashes within a defined range of light intensities and do not show measurable light responses to the brightest lights where their recovery speed cannot catch up with the incoming photons ( Fig. 2A) . Therefore, the test provides an objective index of the operating range of the rods. The eyes over-expressing Meanwhile, the treatment of wildtype mice using the same viral vectors failed to show a measurable change in retinal function ( Supplementary Fig. S3 ).
Delayed and reduced transmission of the altered rod response by rod bipolar cells
An overexpression of R9AP in rods results in faster photoreceptor deactivation kinetics, which allows them to respond to a larger amount of photons. Meanwhile, the accelerated deactivation should also result in a shorter duration of neurotransmitter release at the rod spherule, which may in turn reduce the transmission efficiency of the neural signal to the downstream bipolar cells. To this end, we studied the speed and magnitude of signal transmission from photoreceptors to bipolar cells by analyzing implicit time and amplitudes of the ERG a-wave (originating from the photoreceptors) and the b-wave (originating from bipolar cells) elicited by a short isolated flash in Cnga3-/-mice treated with rAAV2/8.Rho.mR9ap (Fig. 3) . The a-wave trough marks the point at which the bipolar celldriven b-wave becomes detectable. Some increase in the b-wave implicit times without notable change in a-wave implicit times, most likely reflecting a reduced transmission efficiency of the visual signal at the level of the rod bipolar cells, was observed. In addition, b-wave amplitudes probing bipolar cell responses were also reduced. This indicates that the amount of signal transmission to a flash of a given intensity is reduced in treated animals.
However, as there is a relatively large variation of ERG responses between normal individuals, a small delay or reduction in rod response does not necessarily translate into noticeable visual dysfunction 22 .
Photopic shift of rod-mediated cortical responses by over-expression of R9AP
An overexpression of R9AP in rods results in desensitization of the cells and a "photopic shift" of their function. This is accompanied by a small delay and reduction in the bipolar cell response, which may or may not affect visual perception. In order to assess the functional consequence of R9AP overexpression in rods at the level of the visual cortex, visually evoked potentials (VEP) were recorded. Pde6c-/-mice treated with rAAV2/8.Rho.mR9ap were darkadapted and presented with series of flashes of incremental intensities. The intensityresponse profile showed increased P1-N1 and N1-P2 amplitudes particularly at higher flash intensities, consistent with a "photopic shift" of rod-mediated cortical responses by the overexpression of R9AP ( Fig. 4) . Interestingly, the magnitude of the cortical responses as measured by the amplitudes were not reduced at all flash intensities, indicating that the delay and reduction of bipolar responses observed using ERG have minimal effects on the visual perception mediated by altered rod function at some intensities.
Discussion
In the absence of functional cone photoreceptors, vision is dependent on the rods, which normally only function efficiently in lower light conditions. Hence, in individuals with a substantial loss of cones, the low bleaching threshold of remaining rods severely limits the quality of daylight vision. The principle idea of the current study is to "shift" the functional range of the rods towards that of cones through viral vector-mediated over-expression of R9AP, with the aim of compensating for cone dysfunction. The key advantage of this therapeutic approach lies in the fact that the sensitivity of rods is altered through enhancement of a well-defined endogenous regulatory mechanism. This also means that the treated rods may efficiently utilize the downstream rod neural circuit in the retina and in the brain, which ensures the visual system can accommodate the altered retinal function.
Importantly, a recent study has indicated unexpectedly well preserved plasticity of rodmediated visual pathway by showing full restoration of rod-mediated visual acuity in blind adult mice of up to 9 months of age 23 . The treatment relies on the functional augmentation of the abundant rods and does not require the presence of cones. Therefore, therapeutic application may be considered when extensive dysfunction exists due to substantial loss of cones. Thus, forms of cone dystrophy/achromatopsia, cone-rod dystrophy, and acquired cone dysfunction ranging from high myopia to diabetic macular edema may be the suitable targets, as a progressive loss of the cones is documented in patients with these conditions 14, 15, 19, 20 . However, older achromatopsia patients may also benefit from the rod augmentation approach described herein. Not only has some progressive loss of cones been described in achromatopsia patients 15, 24, 25 , but the lack of cone input from birth likely affects the development of physiological cone-dependent visual neuronal circuits including those of the visual cortex 26 , limiting the potential for older individuals to benefit from therapeutic restoration of retinal function.
The obvious drawback of the current approach is the inability to restore high resolution vision in humans which is dependent on the utilization of densely packed cones driving post-receptoral neural circuits in the rod-free fovea. An additional drawback is the persistence of colour vision defects, restoration of which depends on the use of cone visual pigments of different absorption spectra. As the "shift" of rod function involves a desensitization of up to ~2.0 log units, patients may be able to see objects in environment up to ~100 times brighter than before. However, the operating range of intact cones appears to be at least another ~2.0 log units higher than the R9AP-overexpressing rods (Fig. 2) . Thus, the current approach is only partially effective at compensating for the absence of cones.
In conclusion, our approach demonstrates that AAV-mediated over-expression of R9AP in rod photoreceptors might be an effective therapeutic approach to ameliorate cone dysfunction, reducing hypersensitivity to light and improving daylight vision in people affected by advanced cone degeneration caused, for example, by conditions such as inherited disease or wide range of acquired macular dysfunction and degeneration in which conemediated vision is severely affected. 
Methods
Animals
Plasmid constructions and production of recombinant AAV8
The murine R9ap cDNA was PCR amplified from murine retinal cDNA using primers designed to encompass the whole of the coding region. The R9ap cDNA was cloned between the promoter (CMV promoter or bovine rhodopsin promoter) and the SV40 polyadenylation site.
These plasmids were used to generate two pseudotyped AAV2/8 viral vectors, rAAV2/8.CMV.mR9ap and rAAV2/8.Rho.mR9ap, as described previously 29 .
In brief, recombinant AAV2/8 vector was produced through a triple transient transfection method as described previously 30 
Western blotting
The eyes from a 4-week old Cnga3-/-mouse after unilateral sub-retinal injection of rAAV2/8.Rho.mR9ap were collected. After separating the neural retina from the RPE/choroid/sclera complex, tissues were homogenized in RIPA buffer (5 µl/mg tissue) with protease inhibitors (Sigma Aldrich, UK), agitated at 4°C for 30 mins and subsequently centrifuged at 17000xg for 30 mins at 4°C. Supernatants were stored at -80°C until further use. Protein species were resolved as previously described 31 . Briefly, equal amounts of protein extracts (10 μg, denatured in Laemmli's loading buffer) were loaded and resolved on a two-layer SDS-PAGE gel (12% resolving gel; 4% loading gel) together with pre-stained standards (ThermoFisher Scientific, UK). Separated proteins were electro-transferred to PVDF membranes (Millipore, UK) for 1 hour. Membranes were blocked for 1 hr at RT in 3% BSA PBS 0.1% Tween-20 (PBS-T) and then incubated overnight at 4°C with primary antibody (rabbit anti-RGS9, 1:500 in blocking solution; Abcam, UK). After washing three times in PBS-T, membranes were incubated in secondary antibody for 1 hr at RT (goat anti-rabbit HRP conjugated, 1:2500 in blocking solution; ThermoFisher Scientific, UK).
Immune-reactive bands were visualized by enhanced chemiluminescence (ECL plus GE Healthcare, UK). A Fujifilm LAS-1000 Luminescence Image Analyser was used to detect the signal after 1 minute incubation in the reaction mix, by exposing the membranes for 1 -60 seconds.
Electroretinogram (ERG)
ERGs were recorded from both eyes after mice were dark adapted overnight using a commercially available system (Espion E2, Diagnosys LLC, Lowell, MA) as described previously 32 . The animals were anesthetized with an intraperitoneal injection of a 0.007 ml/g mixture of medetomidine hydrochloride (1 mg/ml), ketamine (100 mg/ml), and water at a ratio of 5:3:42 before recording. Pupils were fully dilated using 2.5% phenylephrine and 1.0% tropicamide. Midline subdermal ground and mouth reference electrodes were first placed, followed by positive silver electrodes that were allowed to lightly touch the center of the 33, 34 . Scotopic 6 Hz flicker intensity series were performed as previously reported with a few modifications. 35 We used 17 steps of flash intensities ranging from -6 to 2 log.cd.s/m 2 each separated by 0.5 log unit. For each step, after 10 seconds of adaptation, 600 msec sweeps were averaged 20 times using the same flash condition. Series of dark-adapted responses were also obtained using longer flashes with durations of 20, 100, and 200 msec all at 83.3 cd/m 2 . Standard single flash scotopic recordings were obtained from dark-adapted animals at the following increasing light intensities: -6, -5, -4, -3, -2, -1, 0, 1.0, 1.5, and 1.9 log.cd.s/m 2 . Photopic flash recordings were performed following 5 min light adaptation intervals on a background light intensity of 20 cd/m 2 , which was also used as the background light for the duration of the recordings.
Photopic light intensities used were -2, -1, 0, 1, 1.5, and 1.9 log.cd.s/m 2 .
Visually evoked potentials (VEP)
Before recording VEPs from the visual cortex, electrodes were surgically placed according to the following procedures 36 . Mice were anesthetized by a single intraperitoneal injection of medetomidine hydrochloride (0.6 mg/kg, Meiji Co. Ltd., Tokyo, Japan) and ketamine (36mg/kg, Daiichi-Sankyo, Tokyo, Japan). The part of scalp proximal to the bregma was shaved and disinfected by povidone iodine (Meiji Co. Ltd.). After excising this part of the skin, connective tissues were removed from bone using a scalpel blade. The recording electrodes were placed in the skull overlying the right and left primary visual cortex (3.6-mm caudal to bregma and 2.3-mm lateral) and reference electrode was fixed in the prefrontal cortex (2.0mm rostral to bregma) 37 . Before inserting screw electrodes, small holes (0.5mm diameter) were drilled onto the skull. Three stainless steel pan-head screws (M0.6 x 3mm length) were used for electrodes, which were screwed 1mm into the skull so that the tip of the screw electrode was in contact with the brain surface. These screws are then fixed with cyanoacrylate adhesives (Toa Gosei Co. Ltd., Tokyo, Japan). The ground electrode was clipped onto the tail. Mouse was kept warm on a heating pad through the procedure. After 20 surgical procedures, mice were given a reversal agent, Atipamezole (0.35mg/kg, Meiji Co.
Ltd.) and each animal was kept individually in a separate cage.
The VEP was recorded 7 days after surgically implanting the electrodes. First, mice were dark-adapted overnight, after which pupils were fully dilated with 2.5% phenylephrine and 1.0% tropicamide eye drops. The screw electrodes were connected with recording unit (PuREC, Mayo, Inazawa, Japan) synchronized with LED stimulation coupled with a Ganzfeld dome (LS-100, Mayo, Inazawa, Japan). White flash was presented with intensity increased at 1 log.cd.s/m 2 step (range: -7 to 2 log.cd.s/m 2 ). A band-pass filter (0.3Hz to 50Hz) was applied to the data upon acquisition of the electric responses. 
Figure legends
B.
Delayed b-wave peaks in eyes over-expressing R9AP. A-wave and b-wave implicit times were measured from ERG responses in the treated (red symbols) and the untreated (black symbols) Cnga3-/-eyes (N=5 each). B-wave peak was significantly delayed in response to flashes of higher intensities whereas no difference was observed in a-wave implicit times.
C.
Reduced b-wave amplitudes recorded from Cnga3-/-mice (N=5) in eyes over-
